Once it is established that changes in an exposure variable affect disease risk, questions often arise as to the relative importance of different possible pathways for the effect. For example, if one wishes to evaluate intervention on smoking in the prevention of cardiovascular disease, one confronts the difficulty of effecting changes in smoking habit. Thus, from a public health point of view, one might ask what fraction of smoking's effect could be eliminated by controlling (that is, eliminating) all hyperlipidemia through diet and/or medication. From a mechanistic point of view, one might ask what fraction of smoking's effect is "indirect," in the sense of being mediated through its effect on serum lipid levels, and what fraction of smoking's effect on risk is "direct" relative to hyperlipidemia, in the sense of being mediated through pathways that do not involve serum lipid levels. We note that it is quite plausible that smoking and hyperlipidemia interact to produce clinical cardiovascular disease as, for example, if hyperlipidemia produced coronary artery stenosis, the stenotic artery was blocked by a thrombus caused by smoking-induced platelet aggregation, and the thrombosis resulted in a myocardial infarction. We will show that when smoking and the intermediate hyperlipidemia do not interact to cause disease, the fraction of smoking-induced disease that could be prevented by controlling hyperlipidemia will equal the fraction of disease attributable to the indirect effect of smoking. In the presence of interaction, these fractions will differ.
In Section 1, we show that a common approach to estimating direct effects is often biased, in that it can yield confounded estimates in both observational epidemiologic studies and conventional randomized trials. In Section 2, we show that, even in a randomized crossover trial of exposure, direct and indirect effects cannot be separated without special assumptions. In Sections 3 survival times) , time-dependent covariates, and random outcomes; Refs 1-7 and 11-14 provide examples. We here limit our examples to dichotomous variables and deterministic outcomes; this limitation introduces a certain degree of artificiality into the examples, but it makes the computations transparent.
Consider an exposure or treatment variable X, disease variable D, and covariate Z, all coded 1 = "occurs," 0 = "does not occur"; level 1 of X represents the study exposure, level 1 of D represents the study disease, and level 1 of Z represents the potentially intermediate cofactor. For concreteness, suppose we have a large cohort of male smokers who have agreed to quit smoking if they are randomized to a cessation program, and who will continue smoking otherwise. Let X = 0 for those randomized to quit smoking and X = 1 for those randomized to continue; for simplicity, we will assume that all subjects comply with their assigned treatment, although this assumption would not be essential for the general theory if one were interested in assigned treatment as the study exposure, rather than actual treatment.5 Let D = 1 represent cardiovascular disease, 0 no cardiovascular disease; and let Z = 1 represent hyperlipidemia, 0 normal serum lipids. We suppose that, at baseline, all subjects have normal lipids and no cardiovascular disease. To avoid temporal ambiguity, we shall suppose that, for all subjects, a single serum lipid measurement is made at a time ti after randomization, no subject develops cardiovascular disease before tl, and the outcome of interest is the development of cardiovascular disease by the end of To aid in these deductions, we will cross-classify each subject in the cohort into a 2 Until Section 5, we will also assume that smoking and hyperlipidemia never compete or interact to produce disease. This assumption means that (a) there are no subjects who develop cardiovascular disease if and only if they both continue smoking and develop hyperlipidemia; and (b) there are no subjects who develop cardiovascular disease if and only if they either continue smoking or develop hyperlipidemia. In other words, we assume that (a) cells for which Statement 3 is true but Statements 4-6 are false are empty; and (b) cells for which Statement 6 is false but Statements 3-5 are true are empty. These assumptions further reduce the number of possible causal types to 12. These 12 types are described in Table 1 . Table 2 gives a formal characterization of these 12 types in terms of their outcomes with respect to the occurrence of hyperlipidemia given smoking and nonsmoking, and occurrence of cardiovascular disease under the four possible smoking-serum lipid combinations. A "1" in a column of Table 2 corresponds to the presence of a characteristic, whereas a "0" corresponds to its absence. As we will discuss below, the numbers in parentheses cannot be determined, even in a crossover trial, unless one intervenes to alter the serum lipid status of subjects.
From the descriptions in Tables 1 have no direct effects on cardiovascular disease if P3 = proportions. These proportions are not observable, p5 = P7 = 0, and can have no indirect effects if P4 = 0.
however; instead (subject to random variation), we From Table 2 Table 3 . To understand how Table 3 was con-D = 1; and Z = D = 0). Table 3 gives these expected structed, consider Type 5 subjects. Randomization Table 1 Statement guarantees that the expected proportion of Type 5 subjects among smokers would equal that among nonsmokers: both would equal p5. Type 5 subjects who smoke would develop hyperlipidemia (Z = 1) and cardiovascular disease (D = 1). In contrast, unexposed Type 5 subjects will be normolipidemic (Z = 0) and thus will not develop cardiovascular disease (D = 0). Table 4 rearranges these totals in the more familiar 2 x 2 x 2 table format, and Table 5 displays the incidence proportions (average risks) in terms of the proportions of causal types (the Pi). We note four points about these incidence proportions:
TABLE 2. Occurrence of Hyperlipidemia and Cardiovascular Disease Events under Different Conditions for the Causal Types in
1) The total excess disease incidence (risk difference of cardiovascular disease) due to smoking (which we call the net, total, or overall effect of exposure) is P3 + P4 + P5 + 3) The excess cardiovascular disease incidence due to indirect smoking effects (through hyperlipidemia) is p4. 4) The sum of the quantities in Points 2 and 3 is the quantity in Point 1: if only the 12 types in Tables 1 and 2 are present, the total smoking effect equals the sum of the direct and indirect effects.
As we discuss later, Point 4 is not true in general: if there are subjects for which smoking causes hyperlipidemia and then interacts with hyperlipidemia to cause cardiovascular disease, the sum of the direct and indirect effects can exceed the total excess incidence. The following example shows that, without special assumptions, neither the excess cardiovascular disease incidence due to direct effects nor the excess cardiovascular disease incidence due to indirect effects can be validly estimated or even tested by adjusting the smoking effect for serum lipid status. Pi is the proportion of cohort members of causal type I (i = 0, .., 11), described in Table 1 
Nonidentifiability in a Crossover Trial
Under the model given above or under more complex models, we could still not separate direct and indirect effects even if we could conduct a perfect crossover trial in which there were no carryover effects (that is, in which the results do not depend on the time order of the exposed and nonexposed periods of the trial). In such a trial, we would observe each subject's responses to exposure and to nonexposure, yet we still could not identify the causal type of each subject. In particular, it can be seen from Table 2 that Type 4 and Type 5 subjects would display identical responses to smoking (X = 1) and to quitting (X = 0): both types would develop hyperlipidemia and cardiovascular disease if and only if they continued to smoke, so these types would be indistinguishable. Unfortunately, Type 4 subjects represent indirect effects (P4), whereas Type 5 subjects represent part of the direct effects (p3 + ps + p7). Thus, even in this ideal setting, direct and indirect effects could not be separated. Assuming p5 = 0 (that is, no Type 5 individuals) would render these effects separable in the crossover trial with no carryover effects, but such an assumption would rarely be justified based on available biological knowledge. Table 1 are present and the intervention is completely effective in preventing effects of the intermediate cofactor.
Randomization of Cofactor Intervention
To illustrate this point, assume that the causal model in Tables 1 and 2 holds, and we have a feasible serum lipid intervention with the following properties:
1) The intervention prevents all hyperlipidemia effects but has no effect on cardiovascular disease risk other than through its effect on restoring normal lipid levels; and 2) Aside from the intervention's effect, intervention compliance is not predictive of cardiovascular disease risk.
These two assumptions may be weakened to be conditional on any baseline prognostic factors that are controlled in the analysis. In a trial in which (a) smoking cessation was randomized, and (b) the cofactor intervention is randomly allocated to subjects in whom hyperlipidemia occurs, the expected cardiovascular disease incidences among subjects who do not receive the intervention would appear as in Table 5 . Among subjects who do receive the intervention, however, and thus experience no hyperlipidemia effects, the expected incidence among the exposed, R11B, will be 
Exchangeability Assumptions for Separation of Effects
In the absence of randomization of the intermediate cofactor (hyperlipidemia), it is natural to estimate R11B and ROIB from the estimates of R1o and Roo. This substitution would yield an unbiased estimate if R11B = RIo and ROB = ROO. The latter conditions may be restated as the following "partial exchangeability" assumptions:
El) The expected cardiovascular disease incidence among the smoking normolipidemics equals the incidence that the smoking hyperlipidemics would have had if their hyperlipidemia had been prevented; E2) The expected cardiovascular disease incidence among the quitting normolipidemics equals the incidence that the quitting hyperlipidemics would have had if their hyperlipidemia had been prevented. Without randomization, one must fall back on certain exchangeability assumptions to identify the effects of interest.6 To identify the net (total) effect of smoking in the single 2 x 2 table that ignores hyperlipidemia, we must assume that the exposed and unexposed groups are exchangeable (comparable), that is, that the cardiovascular disease incidence among quitters equals the incidence that the smokers would have had if they had quit. Note, however, that to identify direct and indirect effects, one needs El and E2 in addition to the assumption of exchangeability of the exposed and nonexposed. Thus, one can have confounding for the direct effects but not the net effects. (It is also theoretically possible to have confounding of the net effects but not the direct effects.1-3)
EXPLANATORY COVARIATES (CONFOUNDERS)
Let us return now to our initial study design, in which only the exposure (continued smoking) was randomized, and in which stratification on the intermediate (hyperlipidemia) produced a biased (confounded) estimate of direct effect because the exchangeability assumptions El and E2 were violated. Ordinarily, one attempts to explain confounding by attributing nonexchangeability to the effects of additional covariates that predict risk (given exposure status) and are imbalanced across comparison groups. We will show that it is possible to explain the phenomenon we describe in these terms; nevertheless, one should note three properties of such explanations:
1. Such explanations are not unique, in that there are potentially an infinite number of ways in which uncontrolled covariates may be related to the observed study variables (here, smoking, hyperlipidemia, and cardiovascular disease) and produce exactly the same bias and the same observed distribution of the observed study variables. This property is shared by confounding in the estimation of net effects8; for example, a moderate degree of confounding might be produced by exposure being strongly associated with a moderate risk factor or weakly associated with a strong risk factor. 2. For estimating direct and indirect effects, the confounders may be postexposure covariates and thus may themselves be affected by exposure. In particular, the confounders may themselves be biological intermediates that precede the study intermediate (here, hyperlipidemia) in the causal pathway from exposure to disease; or they may be selection effects of exposure, such as leaving work.'-4 3. If the confounders are identified and measured but are themselves affected by exposure, then simple stratification on the confounders will generally not suffice to control confounding; instead, one will have to resort to the Gcomputation algorithm,1-6 special applications of which are given by Eq 3 above and Eq 5 below. Properties 2 and 3 do not arise in the simple case of estimating the net effect of a point exposure, but they do arise in estimating the effects of a sustained exposure. 17 The general form of the G-computation algorithm requires a more complex structure than we have developed here, but an illustration of Properties 2 and 3 above is given in the following extension of Example 1 to include a three-level covariate C = 0, 1, or 2, which smoking elevates in some (but not all) subjects and is antecedent to hyperlipidemia. We caution that this example shows but one of many ways in which a covariate C could explain the bias seen in the stratified result in Example 1, and it was contrived solely to limit the numerical complexity of illustrating Points 2 and 3; realistic examples can become quite complex (see, for example, Robins2-7).
EXAMPLE 4
Suppose that the 12 types listed in Tables 1 and 2 If we randomize smoking cessation, the expected proportions within each smoking group will appear as in Table 6 . Smoking appears protective in all but one CZ stratum; upon performing an ordinary stratified analysis across the six subtables in Table 6 , we would obtain a risk difference (standardized to the total distribution) of -0.167. In this example, however, smoking is never preventive, and so the conventional approach is biased. The reason that the ordinary stratified estimate is biased is because exposure affects the level of C. (6) This is a generalization of Eqs 3 and 4 to the stratified case. Now, computing from the pik given earlier, one may directly verify that within levels of C and the exposure X, the counterfactual incidences RjmiB equal the actual expected incidences Rjmo among normolipidemics; in other words, the exchangeability assumptions El and E2 hold within strata of C. Substitution of the numbers from Table 6 Hyperlipidemia and cardiovascular disease occurrence for this type would be as given in the first row of When the smoking effect that could be eliminated by controlling hyperlipidemia differs from the indirect effect of smoking, it is the former effect that would be the parameter of public health interest whenever (1) there exists a public health intervention that controls hyperlipidemia (for example, prescription of a cholesterol-lowering drug or diet), but (2) there is no intervention that specifically blocks exposure's effect on elevating serum lipids. On the other hand, if there was no intervention available that could directly lower serum lipids, but there was a drug that would specifically block smoking's ability to elevate lipid levels, then it would be the indirect effects of smoking that would be the parameter of public health interest.
We have seen that the G-computation algorithm Eqs 3 and 4 can fail to estimate the indirect and direct effects of exposure even in the randomized cofactor intervention trial of Section 3. Is there some other computational formula that can estimate the direct and indirect effects in such a trial? We will show that there is no such formula. That is, direct and indirect effects are not identifiable in this trial. To do so, we require a more careful definition of direct and indirect effects. Specifically, we need to distinguish pure indirect effects from total indirect effects. Consider the following causal type: Hyperlipidemia and cardiovascular disease occurrence for this type would be as given in Tables 2 and 7 . It follows that there can be no estimator that can identify the total indirect effects in this trial. If we define the pure direct effects to be the total exposure effects minus the total indirect exposure effects, then it immediately follows that we cannot identify the fraction of the total effects that are pure direct effects either.
Next, define the total direct effects to be the total (net) effect of exposure minus the fraction of pure indirect effects, that is, minus the fraction of Type 4 subjects. Note that Type 13 subjects contribute both to the total direct and total indirect effect, so that the sum of the total direct plus total indirect effect will exceed the total exposure effect if Type 13 subjects are present. We now show that we may be unable to identify (that is, separate) either the pure indirect effect of exposure or the total direct effect in our randomized cofactor intervention trial. Consider two populations. The first is equally divided among Types 4, 10, 13, and 14, where Type 14 is as defined in Table 7 . The second population is composed of only Types 10 and 13 in equal proportion. The two populations would have the same expected outcomes in the randomized cofactor intervention trial, and yet only the first population has Type 4 subjects.
These nonidentifiability results are not so troubling when we again recall that the parameter of public health interest would usually be the smoking effect that could be eliminated by controlling hyperlipidemia, that is, (p4 + P12 + P13). In our randomized cofactor intervention trial, P4 + P12 + P13 can still be estimated by Eq 3 (see Robins1-7). Furthermore, even if there is no intervention on the cofactor, if we can find a covariate C such that El and E2 are satisfied within strata of C and the exposed and unexposed are exchangeable, then (P4 + P12 + P13) can be estimated using the G-computation algorithm Eq 5 or Eq 5'.
We wish to caution the reader who plans to consult Refs 1-7 that the definition of the direct effect of exposure used in this paper differs from that in It can be shown that we could separately identify the pure and total direct and indirect effects if we have data available from a crossover trial with no carryover effects in which both exposure and the cofactor intervention are randomly assigned in both time periods. Even without randomization, we could identify direct and indirect effects in such a crossover study provided both that data on appropriate confounders were available and that there were no carryover effects. Of course, we would rarely have data from such a study. Separation of direct from indirect effects requires a crossover study without carryover effects because of the need to differentiate those exposed hyperlipidemics whose hyperlipidemia is attributable to smoking from those whose hyperlipidemia is not. That is, we need to estimate the joint distribution of the variable representing lipid status under exposure and the variable representing lipid status under nonexposure. To do so, it is necessary to observe the same subject both under exposure and nonexposure.
When the exposure and/or intermediate can also prevent disease or compete to cause disease, the total indirect effect of exposure is defined to be the expected proportion developing disease in the exposed minus the expected proportion in the exposed had exposure's effect on the intermediate Z been blocked (that is, had Z remained at its unexposed value); the total direct effect of exposure is the expected proportion developing disease in the exposed minus the expected proportion in the exposed when unexposed but with Z remaining at its exposed value. The pure direct (indirect) effect of exposure is the total exposure effect minus the total indirect (direct) effect.
Conclusion
When exposure and the intermediate Z interact to cause disease (that is, there are subjects of Types 12, 13, and 14), we cannot hope to separate direct from indirect effects, with the possible exception of certain crossover studies with no carryover effects. Nonetheless, standard adjustment for or stratification on the intermediate will allow us to estimate the exposure effect that would remain after control of the intermediate, provided that the exposed and nonexposed are exchangeable and the additional exchangeability assumptions El and E2 hold.
Assumptions El and E2 may hold only within levels of a covariate (that is, confounder) C that occurs before the intermediate Z but subsequent to exposure. In this case, the exposure effect that could be eliminated by control of the intermediate can be estimated using Eq 5' if the exposed and unexposed are exchangeable as well. Furthermore, the exposure effect that would remain after control of the intermediate can be estimated using Eq 6'. In fact, Eqs 5' and 6' can be used validly to estimate these effects regardless of the mechanism by which exposure and the intermediate jointly affect disease. For instance, estimation validity is not compromised even if exposure, the intermediate, or both, prevent disease in some subjects.1-7 In contrast, conventional simultaneous adjustment for both the confounder C and the intermediate will be biased if C is itself affected by exposure.
In the presence of interaction, it is the potentially estimable parameter-the fraction of the exposure effect that could be eliminated by control of the intermediate-that usually will be the parameter of public health interest, and not the nonidentifiable parameter, the fraction attributable to the indirect effect of exposure.
Implicit in the very definition of the "causal effect of exposure" used in this paper is the assumption that if an event (for example, the presence of hyperlipidemia at ti) would have occurred both under exposure and nonexposure, then exposure was not a cause of the event. We made this assumption even though we recognize that the exposure could have affected the time at which hyperlipidemia first occurred and yet hyperlipidemia would be present at ti regardless of exposure."1-" 4 We conclude with several comments regarding this assumption. First, even if exposure causally influenced the time at which hyperlipidemia develops, it is perfectly logical to say that exposure had no effect on the dichotomous event, the presence or absence of hyperlipidemia at ti. Nonetheless, we agree that, in principle, it is usually preferable to consider the causal effects of an exposure in terms of exposure's effect on the occurrence time of an event.-1114 Robins2-7 provides a rigorous treatment of direct and indirect effects based on a general causal model for the effect of an exposure on time to occurrence. In this paper, however, we chose to use a simple causal model with dichotomous intermediate and outcome variables, because the simple model retains the essential logical and philosophical details of the more general causal model, and yet avoids the mathematical complexities of the general model.
